CLEVELAND, Ohio — One of the Cleveland Clinic’s top neurosurgeons will leave later this year for the Ohio State University Medical Center.
Dr. Ali Rezai, who holds seven patents and whose research has helped launch three life-science companies, will be formally appointed in September but likely will start at OSU in July, university spokesman David Crawford said.
Rezai’s strength is in deep brain stimulation. He was working with Minneapolis medical device maker Medtronic on clinical trials for a deep-brain stimulation device that treats depression, and also has focused on treatments for Parkinson’s disease, depression, obsessive-compulsive disorder, chronic pain and brain injury.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
He is the Clinic’s director of the Center for Neurological Restoration. Autonomic Technologies, CardioNomic and IntElect Medical base their products on Rezai’s research (he is also a board member for Autonomic).
Dr. Andre Machado, whose work also contributed to the three companies connected with Rezai, will now run the Center for Neurological Restoration.
At OSU, Rezai will be vice chair of the Department of Neurological Surgery. He also will oversee the Center for Neuromodulation and areas dealing with functional neurosurgery and neurological innovation. He’ll make $600,000 a year.
Rezai is in Italy and unavailable for comment, according to the Clinic.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
